GSE98212
A third generation therapeutic vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH
Whole  blood transcriptomic profiling indicated that CHAd63-KH induced innate immune responses  characterized by an interferon signature and the presence of activated dendritic cells. Overall design: Whole transcriptome using paired RNA samples with a high dose of the vaccine, pre vaccination and 24 hour post vaccination, and a subsequent experiment showing RNAseq from a low dose of the vaccine pre vaccination, 2hours post, 24 hours post and 14 days post vaccination.